Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis

Next Previous
Search
Trial Profile

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary) ; Ustekinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 15 Jan 2023 Results of pooled analysis of 4 studies ((NCT02319759), DISCOVER-1 (NCT03162796), DISCOVER-2 (NCT03158285), and COSMOS (NCT03796858)) assessing safety of guselkumab in psoriatic arthritis patients, published in The Journal of Rheumatology.
    • 04 Jun 2022 Results of pooled safety data from 5 studies (Phase 2 study and DISCOVER-1&2 trials & VOYAGE-1&2 ) presented at the 23rd Annual Congress of the European League Against Rheumatism.
    • 04 Jun 2022 Results of pooled analysis of four trials (DISCOVER [D]-1&2) , and Ph3b COSMOS and a phase 2 trial) presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top